Full Press Release Details
| CONTACT AT REXAHN: | |
| Amanda Sawney | |
| (240) 268-5300 ext. 300 |
PHARMACEUTICALS, INC. APPOINTS DR. FREDDIE ANN HOFFMAN TO THE BOARD OF
Rexahn Pharmaceuticals, Inc. (OTC BB: RXHN), a biopharmaceutical company
dedicated to the discovery, development, and commercialization of innovative
treatments for cancer, central nervous system disorders, sexual dysfunction
other unmet medical needs, today announced that Dr. Freddie Ann Hoffman has
appointed to fill the vacancy on the Board of Directors created by the
expiration of the term of former director Dr. Young Soon Park. Dr. Hoffman's
one-year appointment was effected by action of the Board of Directors taken
Hoffman, a pediatric hematology-oncologist, currently serves as Chief Executive
Officer of HeteroGeneity, LLC. From 1999 to 2003, Dr. Hoffman served as Senior
Medical Director for New Product Development at Pfizer Consumer Healthcare.
the preceding 13 years, Dr. Hoffman served at the Food & Drug Administration
(FDA) as Chief of the Cytokines, Growth Factors and Oncologic Products Branch
and deputy director of the Medicine Branch, within the Office of the FDA
National Cancer Institute (NCI) as Director of Extramural Clinical Trials.
on today's news, Chang H. Ahn, Ph.D., Chairman and Chief Executive Officer of
the Company, stated, "We are delighted to welcome Dr. Hoffman to Rexahn's Board
of Directors. Dr. Hoffman brings extensive product development and research
capabilities to Rexahn. This experience, including her tenure with the FDA
NCI, will be invaluable to us as we continue to move our product candidates
through the clinical development pipeline, and, ultimately, toward
continued, "Management would also like to take this opportunity to thank Dr.
Park for her service to the Board during the past two years. Dr. Park has been
instrumental in assisting the company as it transitioned into a public company.
Her dedication is deeply appreciated."
Rexahn Pharmaceuticals, Inc.
Pharmaceuticals is a biopharmaceutical company leveraging its unique technology
platform to discover, develop and commercialize innovative treatments for
cancer, central nervous system disorders, sexual dysfunction and other unmet
medical needs. Rexahn's compounds are designed to uniquely treat various disease
states while significantly minimizing side effects in order to allow patients
regain quality of life through therapy. For Additional information about Rexahn
visit www.rexahn.com.
press release contains statements (including projections and business trends)
that are forward-looking statements. Rexahn's actual results may differ
materially from the anticipated results and expectations expressed in these
forward-looking statements as a result of certain risks and uncertainties,
including, Rexahn's lack of profitability, its auditor's going concern
qualification and the need for additional capital to operate its business to
develop its product candidates; the risk that Rexahn's development efforts
relating to its product candidates may not be successful; the possibility of
being unable to obtain regulatory approval of Rexahn's product candidates;
risk that the results of clinical trials may not be completed on time or support
Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates;
Rexahn's reliance on third party researchers and manufacturers to develop its
product candidates; Rexahn's ability to develop and obtain protection of its
intellectual property; and other risk factors set forth from time to time in
filings with the Securities and Exchange Commission. These forward-looking
statements are made as of the date hereof, Rexahn assumes no obligation to
update these forward-looking statements.